Your Position:Products>Antigen/Recombinant Protein

Recombinant Mouse IL-17A (C-6His)

货号:EPT207
  • Price:Negotiable
  • Click:1130

Product Detail

基本信息

Size10ug
Expression HostHuman Cells
TagC-6His

物理性质

Molecular Weight16.2 KDa
Apparent Molecular Weight17-26 KDa, reducing conditions
FormLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
PurityGreater than 95% as determined by reducing SDS-PAGE.

活性与内毒素

Endotoxin LevelLess than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
ActivityLoaded Biotinylated Human IL-17RA -His-Avi(Cat#CY78) on SA Biosensor, can bind Mouse IL-17A-His(Cat#CX14) with an affinity constant of 12.6 nM as determined in BLI assay.

储存与运输

ReconstitutionAlways centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. 
StorageLyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping ConditionThe product is shipped at ambient temperature.
Upon receipt, store it immediately at the temperature listed below.

详细说明

BackgroundInterleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. Mature mouse IL-17A shares 61% and 89% amino acid sequence identity with human and rat IL-17A, respectively. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.